Dermavant Sciences: a strong foundation to propel into the future

2015

September
Dermavant Sciences was founded

2018

March
David Rubenstein, *MD, PhD,* appointed Chief Scientific Officer



Christopher Van Tuyl, *Esq,* appointed General Counsel

July
Purchased rights to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of plaque psoriasis and atopic dermatitis

September
Began preparations for Phase 3 PSOARING clinical program for tapinarof in adults with plaque psoriasis

October
Presented new Phase 2b tapinarof **data on patient-reported outcomes for plaque psoriasis and atopic dermatitis** at the Fall Clinical Dermatology Conference

November
Todd Zavodnick appointed Chief Executive Officer

2019

January
Philip M. Brown, *MD, JD,* appointed Chief Medical Officer

March
Presented Phase 2b secondary **efficacy data of tapinarof in plaque psoriasis** and Phase 2b secondary **outcomes of tapinarof in atopic dermatitis** at the American Academy of Dermatology Annual Meeting

Announced plan to initiate Phase 3 PSOARING clinical program for tapinarof

United States Patent and Trademark Office (USPTO) issued a formulation patent for tapinarof, expiring in 2036

June
Dosed first adult patient in Phase 3 PSOARING clinical trial program for tapinarof in plaque psoriasis

2020

January
Chris Chapman appointed Chief Commercial Officer

Signed exclusive license agreement with Japan Tobacco Inc. for development and commercialization of tapinarof in Japan

April
Completed patient enrollment for two identical Phase 3 clinical trials, PSOARING 1 and PSOARING 2, evaluating tapinarof in adults with plaque psoriasis

May
Efficacy and patient-reported outcomes data from Phase 2b study **evaluating tapinarof in adults with plaque psoriasis** was published in the *Journal of the American Academy of Dermatology (JAAD)*

June
Completed patient enrollment for PSOARING 3, a long-term safety study of tapinarof in adults with plaque psoriasis

Efficacy and patient-reported outcomes data from Phase 2b study **evaluating tapinarof in atopic dermatitis** was published in the *Journal of the American Academy of Dermatology (JAAD)*

August
Announced **new data results** from PSOARING 1 and PSOARING 2 evaluating tapinarof in adults with plaque psoriasis

October
Presented **efficacy and safety data** from Phase 3 PSOARING clinical trial program evaluating tapinarof at the Fall Clinical Dermatology Conference and European Academy of Dermatology and Venereology Congress

November
Fortune named Dermavant one of the **"100 Best Small and Medium Companies to Work For"**

2021

January
Presented **new tapinarof data in adults with plaque psoriasis** from Phase 3 PSOARING clinical trial program at Maui Derm for Dermatologists

February
Announced **new safety and efficacy data** in plaque psoriasis from a planned interim analysis of PSOARING 3

March
Fortune named Dermavant one of the **"Best Workplaces in Health Care & Biopharma,"** the company's second recognition in a row by the outlet

Presented **interim analysis of PSOARING 3** evaluating tapinarof in adults with plaque psoriasis at the Innovations in Dermatology Conference

April
Presented **secondary efficacy and patient-reported outcomes data** from PSOARING 1 and PSOARING 2 evaluating tapinarof in adults with plaque psoriasis at the American Academy of Dermatology Virtual Meeting Experience

May
Michael Swartzburg appointed Chief Financial Officer

New Drug Application submitted to the US FDA for tapinarof for the treatment in adults with plaque psoriasis.

June
Announced $200 million of funding from partners including NovaQuest and Marathon

August
US FDA **accepted the New Drug Application** for tapinarof for the treatment of plaque psoriasis in adult patients

Los Angeles Business Journal named Dermavant one of the **"2021 Best Places to Work in Los Angeles"** and Fortune named Dermavant one of the **"100 Best Small Workplaces,"** the company's third recognition in a row by the outlet

September
Dosed first patient in Phase 3 ADORING clinical trial program for tapinarof in atopic dermatitis in patients down to 2 years of age

Presented **the long-term extension full analysis data** from PSOARING 3 evaluating tapinarof in adults with plaque psoriasis at the European Academy of Dermatology and Venereology Congress, confirming previously reported results from the interim analysis

December
Data from the pivotal Phase 3 trials, PSOARING 1 and PSOARING 2, evaluating tapinarof in adults with plaque psoriasis was published in *The New England Journal of Medicine (NEJM)*

2022

January
Presented **new patient satisfaction data** from PSOARING 3 evaluating tapinarof in adults with plaque psoriasis at the 2022 Winter Clinical Dermatology Conference

March
Presented new data across **secondary efficacy outcomes, quality of life and tolerability scores** from PSOARING 3 evaluating tapinarof in adults with plaque psoriasis at the 2022 American Academy of Dermatology Annual Meeting

Announced grand opening of new headquarters in Southlake, Texas, **marking Dermavant's third location in the US**

May
US FDA approved VTAMA® (tapinarof) cream, 1% for the topical treatment of plaque psoriasis in adults — the first and only FDA-approved steroid-free topical medication in its class

Future

With **150+ YEARS** of combined dermatology expertise from the Dermavant leadership team working towards our goal of transforming lives, the future at Dermavant is bright.

WE ARE EXCITED FOR YOU TO SEE WHAT'S NEXT!

IMPORTANT SAFETY INFORMATION

Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. **Adverse Events:** The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching, redness, peeling, burning, or stinging).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information.